JP7414281B2 - 初期心不全の診断方法 - Google Patents
初期心不全の診断方法 Download PDFInfo
- Publication number
- JP7414281B2 JP7414281B2 JP2020507022A JP2020507022A JP7414281B2 JP 7414281 B2 JP7414281 B2 JP 7414281B2 JP 2020507022 A JP2020507022 A JP 2020507022A JP 2020507022 A JP2020507022 A JP 2020507022A JP 7414281 B2 JP7414281 B2 JP 7414281B2
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- subject
- heart failure
- biomarker
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010019280 Heart failures Diseases 0.000 title description 105
- 239000000090 biomarker Substances 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 239000012472 biological sample Substances 0.000 claims description 51
- 210000003296 saliva Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 102100038297 Kallikrein-1 Human genes 0.000 claims description 35
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims description 33
- 101001055314 Homo sapiens Immunoglobulin heavy constant alpha 2 Proteins 0.000 claims description 21
- 102100026216 Immunoglobulin heavy constant alpha 2 Human genes 0.000 claims description 21
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 claims description 18
- 101710144432 Dihydrolipoyl dehydrogenase, mitochondrial Proteins 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 17
- 102100030972 Coatomer subunit beta Human genes 0.000 claims description 15
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 15
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- 101000919970 Homo sapiens Coatomer subunit beta Proteins 0.000 claims description 14
- -1 KV110 Proteins 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 56
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 21
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 20
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 description 20
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 18
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 4
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004878 Gelsolin Human genes 0.000 description 2
- 108090001064 Gelsolin Proteins 0.000 description 2
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 101710132152 Immunoglobulin J chain Proteins 0.000 description 2
- 101710176219 Kallikrein-1 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 101710186199 Coatomer subunit beta Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000007356 Cornified Envelope Proline-Rich Proteins Human genes 0.000 description 1
- 108010032748 Cornified Envelope Proline-Rich Proteins Proteins 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100040236 Immunoglobulin heavy variable 3-33 Human genes 0.000 description 1
- 101710111842 Immunoglobulin heavy variable 3-33 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100029958 T-complex protein 1 subunit delta Human genes 0.000 description 1
- 101710179457 T-complex protein 1 subunit delta Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- UOUXAYAIONPXDH-UHFFFAOYSA-M flucarbazone-sodium Chemical compound [Na+].O=C1N(C)C(OC)=NN1C(=O)[N-]S(=O)(=O)C1=CC=CC=C1OC(F)(F)F UOUXAYAIONPXDH-UHFFFAOYSA-M 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrotherapy Devices (AREA)
- External Artificial Organs (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903138A AU2017903138A0 (en) | 2017-08-08 | Methods for Diagnosis of Early Stage Heart Failure | |
| AU2017903138 | 2017-08-08 | ||
| PCT/AU2018/050827 WO2019028507A1 (en) | 2017-08-08 | 2018-08-08 | METHODS OF DIAGNOSING PRECOCUS STAGES OF CARDIAC INSUFFICIENCY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530120A JP2020530120A (ja) | 2020-10-15 |
| JP2020530120A5 JP2020530120A5 (enExample) | 2021-09-16 |
| JP7414281B2 true JP7414281B2 (ja) | 2024-01-16 |
Family
ID=65273054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507022A Active JP7414281B2 (ja) | 2017-08-08 | 2018-08-08 | 初期心不全の診断方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200174021A1 (enExample) |
| EP (1) | EP3665483A4 (enExample) |
| JP (1) | JP7414281B2 (enExample) |
| CN (1) | CN111465857A (enExample) |
| AU (2) | AU2018315056B2 (enExample) |
| WO (1) | WO2019028507A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021283390A1 (en) | 2020-06-03 | 2023-01-19 | Esn Cleer | Biomarker identification for imminent and/or impending heart failure |
| CN115327129A (zh) * | 2022-07-05 | 2022-11-11 | 上海交通大学医学院附属上海儿童医学中心 | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005110602A (ja) | 2003-10-09 | 2005-04-28 | Sumitomo Pharmaceut Co Ltd | アトピー性皮膚炎の疾患マーカー及びその利用 |
| JP2008541078A (ja) | 2005-05-09 | 2008-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | 初期段階の心機能異常を診断または予測するための装置および方法 |
| US20150072360A1 (en) | 2011-12-14 | 2015-03-12 | The Johns Hopkins University | Biomarkers of pulmonary hypertension |
| JP2015529817A (ja) | 2012-08-15 | 2015-10-08 | ザ プロクター アンド ギャンブルカンパニー | ヒトエックスビボ皮膚モデル及び皮膚炎症のモジュレータを特定する方法におけるその使用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002094870A2 (en) * | 2000-11-02 | 2002-11-28 | Curagen Corporation | Proteins and nucleic acids encoding same |
| US20030113726A1 (en) * | 2000-12-04 | 2003-06-19 | Zenta Tsuchihashi | Human single nucleotide polymorphisms |
| US20040033582A1 (en) * | 2002-06-03 | 2004-02-19 | Manling-Ma Edmonds | Human single nucleotide polymorphisms |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| WO2006008002A2 (en) * | 2004-07-23 | 2006-01-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1) |
| WO2006015209A2 (en) * | 2004-07-29 | 2006-02-09 | Stem Cell Innovations, Inc. | Differentiation of stem cells |
| WO2007047995A2 (en) * | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| EP2302395B1 (en) * | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| JP2009541287A (ja) * | 2006-06-20 | 2009-11-26 | リポペプチド・アクチエボラーグ | 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用 |
| WO2008000067A1 (en) * | 2006-06-26 | 2008-01-03 | Vasogen Ireland Limited | Treatment of mild chronic heart failure in human patients |
| CA2791144C (en) * | 2006-07-05 | 2019-04-09 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| DK2046951T5 (da) * | 2006-07-05 | 2012-01-23 | Catalyst Biosciences Inc | Proteasesreeningsmetoder og proteaser identificeret dermed |
| US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| US20100267052A1 (en) * | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| CA2671267A1 (en) * | 2006-11-30 | 2008-06-05 | Navigenics Inc. | Genetic analysis systems and methods |
| ZA200903761B (en) * | 2006-11-30 | 2010-08-25 | Navigenics Inc | Genetic analysis systems and methods |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| WO2011133770A2 (en) * | 2010-04-21 | 2011-10-27 | Board Of Regents Of The University Of Texas System | Salivary protein markers for detection of breast cancer |
| EP2671083A1 (en) * | 2011-02-03 | 2013-12-11 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| US20150045245A1 (en) * | 2011-12-08 | 2015-02-12 | Biocartis Nv | Biomarkers and test panels useful in systemic inflammatory conditions |
| US10131709B2 (en) * | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| EP2877213B1 (en) * | 2012-07-25 | 2020-12-02 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| CN104049082B (zh) * | 2014-05-30 | 2016-03-16 | 华中科技大学同济医学院附属同济医院 | 人组织激肽释放酶活性检测试剂盒及其应用 |
| CN105987998B (zh) * | 2015-01-30 | 2017-12-29 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1elisa定量检测试剂盒 |
| EP3259594A4 (en) * | 2015-02-20 | 2018-12-26 | The Johns Hopkins University | Biomarkers of myocardial injury |
-
2018
- 2018-08-08 WO PCT/AU2018/050827 patent/WO2019028507A1/en not_active Ceased
- 2018-08-08 CN CN201880063136.3A patent/CN111465857A/zh active Pending
- 2018-08-08 EP EP18844704.9A patent/EP3665483A4/en not_active Withdrawn
- 2018-08-08 AU AU2018315056A patent/AU2018315056B2/en active Active
- 2018-08-08 JP JP2020507022A patent/JP7414281B2/ja active Active
- 2018-08-08 US US16/636,403 patent/US20200174021A1/en not_active Abandoned
-
2021
- 2021-09-13 AU AU2021232662A patent/AU2021232662B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005110602A (ja) | 2003-10-09 | 2005-04-28 | Sumitomo Pharmaceut Co Ltd | アトピー性皮膚炎の疾患マーカー及びその利用 |
| JP2008541078A (ja) | 2005-05-09 | 2008-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | 初期段階の心機能異常を診断または予測するための装置および方法 |
| US20150072360A1 (en) | 2011-12-14 | 2015-03-12 | The Johns Hopkins University | Biomarkers of pulmonary hypertension |
| JP2015529817A (ja) | 2012-08-15 | 2015-10-08 | ザ プロクター アンド ギャンブルカンパニー | ヒトエックスビボ皮膚モデル及び皮膚炎症のモジュレータを特定する方法におけるその使用 |
Non-Patent Citations (3)
| Title |
|---|
| Jason M. Tonne，Secretion of Glycosylated Pro-B-Type Natriuretic Peptide from Normal Cardiomyocytes，Clinical Chemistry，2011年，Vol.57 No.6，Page.864-873 |
| Xi Zhang，Identification and Validation of a Salivary Protein Panel to Detect Heart Failure Early，Theranostics，2017年09月26日，Vol.7 No.18，Page.4350-4358 |
| Yunxia Wan，A multimarker approach to diagnose and stratify heart failure，International Journal of Cardiology，2014年12月23日，Vol.181，Page.369-375 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018315056B2 (en) | 2021-06-17 |
| US20200174021A1 (en) | 2020-06-04 |
| AU2021232662B2 (en) | 2023-06-01 |
| AU2018315056A1 (en) | 2020-03-26 |
| AU2021232662A1 (en) | 2021-10-07 |
| JP2020530120A (ja) | 2020-10-15 |
| EP3665483A1 (en) | 2020-06-17 |
| CN111465857A (zh) | 2020-07-28 |
| EP3665483A4 (en) | 2021-07-14 |
| WO2019028507A1 (en) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2353011B1 (en) | Biomarker for the prediction of first adverse events | |
| CN104303061B (zh) | 患有疑似慢性心力衰竭的患者中不良事件的预后 | |
| US20110124122A1 (en) | Biomarkers and assays for myocardial infarction | |
| AU2021232662B2 (en) | Markers relating to early stage heart failure | |
| US11740245B2 (en) | Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients | |
| JP7457300B2 (ja) | 神経変性疾患の診断用ペプチドマーカー | |
| US10557860B2 (en) | Circulating pulmonary hypertension biomarker | |
| Rossi et al. | Proteomics for the study of new biomarkers in Fabry disease: State of the art | |
| JP6595641B2 (ja) | 心不全の診断 | |
| Elmas et al. | Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease | |
| US20210270835A1 (en) | Biomarkers for urothelial carcinoma and applications thereof | |
| WO2010136232A1 (en) | In vitro method suitable for patients suffering from cis for the early diagnosis or prognosis of multiple sclerosis | |
| US20240418729A1 (en) | Method for detection and quantification of immunoglobulin free light chain dimers | |
| US20100035263A1 (en) | Biomarkers for renal disease | |
| JP7336097B2 (ja) | 乳がんに関するペプチドマーカー | |
| JP2024117521A (ja) | 膵臓がんの検出方法 | |
| JP2017072460A (ja) | 虚血性疾患の診断マーカー | |
| JP2018163071A (ja) | 関節リウマチに関するペプチドマーカー | |
| HK1152751A (en) | Methods for detecting major adverse cardiovascular and cerebrovascular events | |
| HK1203611B (en) | Prognosis of adverse events in patients with suspected chronic heart failure | |
| HK1164999A (en) | Biomarker for the prediction of first adverse events |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210804 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210804 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230328 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230928 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7414281 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |